sale y/i beat our/street
estim better perform
rais sale guidanc gross margin lag
estim acceler invest expand capac oper leverag
off-set led better oper margin vs
pharmaci channel expans continu manag announc
provid pharmaci coverag competit remain high particularli libr
pend manag note market expans underway new
market opportun latter point increas invest non-
enhanc importantli remain track late
us/ou sale exceed forecast
intern manag note strength core market new signific
expans opportun japan remain key new opportun medium
term gm impact increment infrastructur invest
 line estim sg significantli lower
note cover live plan offer
pharmaci channel headwind revenue/pati access/volum
benefit potenti opex save pharmaci channel off-set
price manufactur ramp az facil launch
new low-cost transmitt gm expect approach exit
guidanc manag rais sale guidanc impli
y/i growth gm expect previous
capac invest non-gaap oper margin slightli rais
impli y/i margin expans adjust ebitda margin
remain guidanc build revenue-per-pati headwind
pipelin track small trial on-going system featur get refin
recal significantli downsiz one-piec dispos sensor
extend wear also lower-cost design provid flexibl
enhanc expect also acceler effort new
estim sale estim rise us
y/i ou ep rise higher
sale oper leverag forecast sale
ep ou intens potenti upsid driver
year price histori
medic devic
compani focus design
develop continu glucos
monitor cgm system diabet
patient lead product cgm
analyst certif import disclosur see disclosur
cgm penetr type diabet reach
next year
us growth acceler mid-to-high teen market
channel expans well medicar contribut off-set lower
modest acceler intens type patient non-medicar
type contribut sale beyond modest current
under-penetrated patient popul robust pipelin
forecast solid sale growth next sever year
partnership verili devic new market opportun
launch sensor-aug pump pump partner
competitor launch lead greater market share loss
price target driven blend discount cash flow assum weight averag cost capit
termin growth rate base estim ebitda price target impli ev/sal multipl
risk includ competit slowdown revenu due macroeconom pressur clinic trial fda risk
